Download PDF
Pharmacopsychiatry 2012; 45(07): 297-299
DOI: 10.1055/s-0032-1306312
Letter
© Georg Thieme Verlag KG Stuttgart · New York

Pregabalin-associated Elevation of Clozapine Serum Levels

M. Gahr
1   Department of Psychiatry and Psychotherapy III, University ­Hospital of Ulm, Ulm University, Ulm, Germany
,
M. M. Schmid
1   Department of Psychiatry and Psychotherapy III, University ­Hospital of Ulm, Ulm University, Ulm, Germany
,
C. Schönfeldt-Lecuona
1   Department of Psychiatry and Psychotherapy III, University ­Hospital of Ulm, Ulm University, Ulm, Germany
› Author Affiliations
Further Information

Publication History

received 25 January 2012
revised 13 February 2012

accepted 14 February 2012

Publication Date:
03 April 2012 (online)

Also available at
    Permissions and Reprints

Corrected by:

Pregabalin-associated Elevation of Clozapine Serum LevelsPharmacopsychiatry 2012; 45(07): e2-e2
DOI: 10.1055/s-0032-1311645

Abstract

We report our experience with a 34-year-old patient with schizophrenia, paranoid subtype, who demonstrated an elevation of clozapine serum levels subsequent to pregabalin comedication used for the treatment of schizophrenic anxiety. This observation turned to be dose-dependent. Although the pharmacokinetic profile of pregabalin suggests an exclusive renal elimination, our report supports the presumption of a possible direct or indirect hepatic “effect” of pregabalin.

Key words

pharmacokinetics - schizophrenia treatment - antipsychotic drugs - adverse effects - schizophrenia
 

  • References

  • 1 Sills G. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 2006; 6: 108-113
    CrossrefPubMedGoogle Scholar
  • 2 Lanneau C, Green A, Hirst W et al. Gabapentin is not a GABAB receptor agonist. Neuropsychopharmacology 2001; 41: 965-975
    PubMedGoogle Scholar
  • 3 Field M, Cox P, Stott E et al. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA 2006; 103: 17537-17542
    CrossrefPubMedGoogle Scholar
  • 4 Taylor C. The biology and pharmacology of calcium channel alpha2-delta proteins. Pfizer Satellite Symposium to the 2003 Society for Neuroscience Meeting. Sheraton New Orleans Hotel, New Orleans, LA November 10, 2003. CNS Drug Rev 2004; 10: 183-188
    PubMedGoogle Scholar
  • 5 Errante L, Petroff O. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure 2003; 12: 300-306
    CrossrefPubMedGoogle Scholar
  • 6 Cunningham M, Woodhall G, Thompson S et al. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci 2004; 20: 1566-1576
    CrossrefPubMedGoogle Scholar
  • 7 Dooley D, Donovan C, Pugsley T. Stimulus-dependent modulation of [3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000; 295: 1086-1093
    PubMedGoogle Scholar
  • 8 Maneuf Y, Hughes J, McKnight A. Gabapentin inhibits the substance P-facilitated K+-evoked release of [3H]glutamate from rat caudal trigeminal nucleus slices. Pain 2001; 93: 191-196
    CrossrefPubMedGoogle Scholar
  • 9 Chizh B, Gohring M, Troster A et al. Effects of oral pregabalin and aprepitant on pain and central sensitization in the electrical hyperalgesia model in human volunteers. Br J Anaesth 2007; 98: 246-254
    CrossrefPubMedGoogle Scholar
  • 10 Chen S, Xu Z, Pan H. Stereospecific effect of pregabalin on ectopic afferent discharges and neuropathic pain induced by sciatic nerve ligation in rats. Anesthesiology 2001; 95: 1473-1479
    CrossrefPubMedGoogle Scholar
  • 11 Lyrica (pregablin) capsules [prescribing information]. New York, NY: Pfizer, Inc; Revised 06/2011
  • 12 Brodie M, Wilson E, Wesche D et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 2005; 46: 1407-1413
    CrossrefPubMedGoogle Scholar
  • 13 Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006; 61: 246-255
    CrossrefPubMedGoogle Scholar
  • 14 Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical pratice. Epilepsia 2004; 45 (Suppl. 06) 13-18
    PubMedGoogle Scholar
  • 15 Tassone D, Boyce E, Guyer J et al. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007; 29: 26-48
    CrossrefPubMedGoogle Scholar
  • 16 Dogan S, Ozberk S, Yurci A. Pregabalin-induced hetatotoxicity. Eur J Gastroenterol Hepatol 2011; 23: 628
    CrossrefPubMedGoogle Scholar
  • 17 Sendra J, Junyent T, Pellicer M. Pregabalin-induced hepatotoxicity. Ann Pharmacother 2011; 45: e32
    CrossrefPubMedGoogle Scholar
  • 18 Schönfeldt-Lecuona C, Wolf R, Osterfeld N et al. Pregabalin in the treatment of schizophrenic anxiety. Pharmacopsychiatry 2008; 41: 1-2
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Englisch S, Esser A, Enning F et al. Augmentation with pregabalin in schizophrenia. J Clin Psychopharmacol 2010; 30: 437-440
    CrossrefPubMedGoogle Scholar
  • 20 Naranjo C, Busto U, Sellers E et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245
    CrossrefPubMedGoogle Scholar
  • 21 Englisch S, Alm B, Meyer-Lindenberg A et al. Pregabalin-associated increase of clozapine serum levels. J Clin Psychopharmacol 2012; 32: 127
    CrossrefPubMedGoogle Scholar
  • 22 Prior T, Baker G. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003; 28: 99-112
    PubMedGoogle Scholar